reports
IGC Announces Rebranding, Changes Name to IGC Pharma, Inc.
IGC Announces Rebranding, Changes Name to IGC Pharma, Inc. POTOMAC, Md., March 20, 2023 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it will begin operating under the new name IGC Pharma, Inc., (dba IGC) effective March 30, 2023, as part of a rebranding strategy that better reflects IGC Pharma’s strategic focus and vision for the future. Our common stock will continue to be quoted on the NYSE American under the same symbol IGC. Trading of our common stock under our new name will commence on March 31, 2023. Our CUSIP ...
IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, ...
IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022 POTOMAC, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (dba IGC, Inc.) (NYSE American: IGC) (“IGC” or the “Company”) today reported its third fiscal quarter 2023 financial results. Third Fiscal Quarter 2023 Highlights: The Company expanded the number of sites participating in its Phase 2 clinical trial on IGC-AD1 for agitation in dementia from Alzheimer’s disease to a total of four – three in the U. S. and one in Canada. The Company is encoura...
IGC to be Featured in Feb. 10 Radius Research Investor Webinar
IGC to be Featured in Feb. 10 Radius Research Investor Webinar POTOMAC, Md., Feb. 08, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: ) (“IGC” or the “Company”) today announces that Ram Mukunda, CEO, and Claudia Grimaldi, PFO, will be featured in an investor webinar hosted by Radius Research on Friday, Feb. 10, at 12:30 p.m. ET. They will discuss the Company’s Phase 2 trial for its drug candidate IGC-AD1 in treating agitation in dementia patients suffering from Alzheimer’s and will participate in a question and answer session. Investors can ...
IGC Receives No Objection Letter from Health Canada
IGC Receives No Objection Letter from Health Canada POTOMAC, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”) today announces it has received a no objection letter from Health Canada for approval of its trial, “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease.” The no objection letter provides the acknowledgement of IGC-AD1’s drug candidacy and the authority to procee...
IGC Announces Updated Life Sciences Presentation
IGC Announces Updated Life Sciences Presentation POTOMAC, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today announces that a life sciences presentation has been filed with the SEC on Form 8K and is available at . The presentation is also published on the Company’s website . The presentation provides an overview of the Company’s initiatives in life sciences, including its focus on low-dose THC-based drug formulation and disease treatment and its various lines of cannabinoid-based consumer products. About IGC:...
IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol R...
IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act POTOMAC, Md., Dec. 07, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”), applauds the signing of the Medical Marijuana and Cannabidiol Research Expansion Act (“the Act”), which was signed into law by President Biden on Friday Dec. 2, 2022. The law provides legislation establishing a new registration process for conducting research on marijuana and for manufacturing marijuana products for research purposes and drug developmen...
IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD...
POTOMAC, Md.--(BUSINESS WIRE)-- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), announced that it has begun “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease”. The Company has commenced the Phase 2 study at two U.S. sites with plans to add between three to five additional sites in the United States, Canada, and possibly South America to increase population diversity, promoting both the inclusion of underrepresented populations...
IGC to Present at the RHK 2022 Disruptive Growth Conference
IGC to Present at the RHK 2022 Disruptive Growth Conference POTOMAC, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”) today announced that Ram Mukunda, Chief Executive Officer, will be presenting at the RHK Disruptive Growth Conference in New York City on Monday, December 5 at 11:20 am ET and will be available for one-on-one meetings on Monday, December 5 and Tuesday, December 6. About IGC India Globalization Capital Inc. develops advanced cannabinoid-based formulations for treating diseases, including but not limited ...
IGC Announces Financial Results for Fiscal Year Ended March 31, 2018
IGC Announces Financial Results for Fiscal Year Ended March 31, 2018 BETHESDA, Md., June 21, 2018 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC) announces financial results for the fiscal year ended March 31, 2018. “In fiscal 2018, the Company’s focus was to develop, manufacture, and lay the foundation to commercialize our lead product Hyalolex, an alternative oral cannabinoid-based therapy for the treatment of symptoms associated with Alzheimer’s. The commercialization of Hyalolex through medical dispensaries in select states is expected to commence in the se...
A director sold 300,000 shares at 0.451USD and
A director at India Globalization Capital Inc sold 300,000 shares at 0.451USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
- Matthew Read
India at a significant discount
In August, India Capital Growth (IGC) saw the successful conversion of its subscription share issue, which increased net assets by 29.2% before costs. This expansion should improve liquidity in the company’s shares and lower its ongoing charges going forward. However, despite these positive developments, an improving outlook for India and superior performance relative to its immediate peers, IGC’s discount has widened both absolutely and relative to its peer group. We feel this is not justified ...
- Matthew Read
Indian powerhouse
”‹India Capital Growth’s (IGC’s) net asset value (NAV) is up 28.8% since QuotedData’s last note was published on 23 March 2016 (its price is up 20.1%) yet, in recent weeks, its discount has widened to 20.4%. The managers cannot see any obvious reason why the discount should be widening. India shines as a bright spot in a world beset by economic problems: GDP growth is running at 7.9%. The managers of IGC believe, that whilst a series of sometimes painful, but very necessary adjustments is ongoi...
- Matthew Read
Indian powerhouse
”‹IGC’s NAV is up 28.8% since our last note was published on 23 March 2016 (its price is up 20.1%) yet, in recent weeks, its discount has widened to 20.4%. There is no good reason why the discount should be widening, in our view.India shines as a bright spot in a world beset by economic problems: GDP growth is running at 7.9%. The managers of India Capital Growth (IGC) believe, that whilst a series of sometimes painful but very necessary adjustments is ongoing, India’s economy is now on a more s...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.